Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
 
Home / ASCO Direct Highlights / CAR T-Cell Therapies Online Course

CAR T-Cell Therapies Online Course

ASCO® DIRECT Highlights 2019:  CAR T-Cell Therapies 

Target Audience

The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

Overview

ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

Objectives

At the end of this educational activity, participants should be able to:

  • Review highlights of the advances in clinical and translational research in CAR T-cell therapeutics presented at the 2019 ASCO® Annual Meeting
  • Identify emerging trends and strategies designed to improve the quality of care for patients receiving CAR T-cell therapies 

Faculty

Keri Maher, DO, MS
Assistant Professor of Medicine
Hematopoietic Cellular Therapy and Transplant
University of Arizona Cancer Center
University of Arizona, Tucson

Access Course
Link Coming Soon

Supporter

This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co., Inc. and TESARO, Inc.